CRDL (Cardiol Therapeutics Inc.) Volume dana dhuwit perusahaan

Logo grafis Cardiol Therapeutics Inc (CRDL)

The strengthening position of Cardiol Therapeutics (CRDL) is based on patents for treating myocarditis with ultra-pure cannabidiol. Geographic coverage in Europe and the US hedges regulatory risks, although cash flows remain volatile until testing is completed. The amount of operating cash reflects the market consensus on liquidity, where the current value equals 0.02, which determines the issuer's current financial reserve.

Total volume dana dhuwit perusahaan: Cardiol Therapeutics (CRDL) kanggo 04.07.2022 - 21.11.2026

Rincian analitis perusahaan Cardiol Therapeutics

- nilai saham lan prakiraan konsensus rega:
- indikator valuasi pasar bisnis:
Ringkesan analisis perusahaan:cardiolrx.com
Sampel barang cardiolrx.com

Clinical trials of anti-inflammatory agents by Cardiol Therapeutics (CRDL) require significant expenditures, which temporarily limits operational efficiency during the pre-profit stage. By analyzing the size of the cash reserve, the investor assesses the total liquidity balance to monitor the burn rate and prevent cash flow gaps, which is critical for maintaining the company's capitalization until the development phases are completed.